ライフサイエンスコーパス: VLP

1 VLP-based vaccines showed significantly better neutraliz

2 VLPs are formed by structural viral proteins that inhere

3 aining either 15 microg or 50 microg of GI.1 VLP and 50 microg GII.4 VLP (15/50 and 50/50 formulation

4 era from mice immunized with a single GII.17 VLP identified antigenic shifts between each cluster of

5 or 50 microg of GI.1 VLP and 50 microg GII.4 VLP (15/50 and 50/50 formulations) adjuvanted with monop

6 issociation constants (KD < 10 nM) for GII.4 VLP.

7 Immunization with DENV1-4 VLPs as individual, monovalent vaccines elicited strong

8 For use as a tetravalent vaccine, DENV1-4 VLPs elicited high levels of neutralization activity aga

9 virus-like-particles (VLPs), GI.1 and GII.4 VLPs.

10 ctron microscopy reconstruction of the T = 4 VLPs assembled in the presence of one of the RNAs reveal

11 LPs) against pig gastric mucin (PGM) using 4 VLPs that represent different GII.4 norovirus variants i

12 We created recombinant DENV1 to -4 (DENV1-4) VLPs by coexpressing precursor membrane (prM) and envelo

13 tential applications in the development of a VLP vaccine as well as small-molecule drugs targeting as

14 We demonstrated that mice maintained on a VLP diet succumb to lethal challenge at greater rates th

15 tibody-dependent phagocytic activity against VLP-coated beads, and antibody breadth and neutralizing

16 binding affinity for four synbodies against VLPs from multiple GI and GII genotypes and found that t

17 Vmac251 challenges, two of seven DNA/MVA and VLP (DM+VLP)-vaccinated animals were completely protecte

18 e packaged in one VLP and mixed with another VLP displaying the antigen prior to administration in vi

19 antity of antibodies, while SpyCatcher-AP205-VLPs elicited the highest quality anti-Pfs25 antibodies

20 gh genome-free PV ECs have been expressed as VLPs in a variety of systems, their inherent antigenic i

21 Stabilized ECs, expressed recombinantly as VLPs, could be ideal candidate vaccines for a polio-free

22 w reports are available concerning authentic VLP production or testing, in large part because VLP pro

23 ntification and differentiation of HIV-based VLPs from cellular vesicles has been performed under amb

24 access to the virus capsid of the HIV-based VLPs.

25 production or testing, in large part because VLP production is inefficient and the mechanisms underly

26 there was no virus-induced mortality in both VLP and AP groups of mice when either group was immunize

27 Both VLPs efficiently reached the same draining lymph node wh

28 gn protein, Renilla luciferase, into budding VLPs.

29 Both candidate VLP vaccines were well tolerated and elicited robust imm

30 ons between CDots and the negatively charged VLPs.

31 Therefore, the novel HPV-18 L1/L2 chimeric VLP (alone or in combination with HPV-16 and HPV-18 L1 V

32 The chimeric VLP consisted of HPV-18 L1 with insertions of HPV-33 L2

33 long-lasting protective efficacy of chimeric VLPs (cVLPs) containing influenza HA and GPI-anchored CC

34 Here, we report the engineering of chimeric VLPs, derived from rabbit hemorrhagic disease virus (RHD

35 Several chimeric VLPs were constructed by inserting L2 epitopes within th

36 The immunogenic potential of the chimeric VLPs was analyzed in the mouse model.

37 ge were vaccines that contained the P1 COBRA VLP and either the X3 or X6 COBRA VLP vaccine.

38 e P1 COBRA VLP and either the X3 or X6 COBRA VLP vaccine.

39 We expressed in E. coli VLPs from the bacteriophage AP205 genetically fused to S

40 ses were also detected with CCL28-containing VLPs compared to other groups.

41 The CCL28-containing VLPs showed complete and 80% protection, when vaccinated

42 taining VLPs or the wild-type F/F-containing VLPs after a single immunization but not after prime and

43 f mice, without adjuvant, pre-F/F-containing VLPs induced significantly higher neutralizing antibody

44 antibody titers than the post-F/F-containing VLPs or the wild-type F/F-containing VLPs after a single

45 diversity of L1 VLPs, this vaccine contains VLPs based on a recombinant chimera of two highly conser

46 However, decorating VLPs with target-antigens by genetic fusion or chemical

47 blish a platform for irreversibly decorating VLPs simply by mixing with protein antigen.

48 vious attempts of other groups to use dengue VLPs resulted in generally poor yields.

49 e results suggest that our strategy for DENV VLP production is applicable to other flavivirus VLP vac

50 or vaccine formulation than adding different VLPs for each HPV.

51 parative analyses-Gag cellular distribution, VLP size, and basic morphological features using Gag exp

52 higher acute viremia was observed in the DM+VLP group, likely due to a slower recall of Gag-specific

53 challenges, two of seven DNA/MVA and VLP (DM+VLP)-vaccinated animals were completely protected compar

54 be incorporated as a passenger into F-driven VLPs, provided that the F protein was competent for endo

55 an those with the DNA vaccines, with C-prM-E VLPs giving slightly higher titers than those with prM-E

56 The prM-E VLPs induced a strong neutralizing antibody response in

57 The superiority of C-prM-E VLPs suggests that inclusion of capsid may have benefits

58 Furthermore, C-prM-E and prM-E VLPs were tested as vaccine candidates in mice and compa

59 slightly higher titers than those with prM-E VLPs.

60 ion of human SOCS3 enhances budding of Ebola VLPs and infectious virus via a mechanism linked to the

61 describes a safe, effective, and economical VLP-based vaccine against ZIKV.IMPORTANCE To address the

62 necessary for M-NP interaction and efficient VLP production.

63 ions of the F CT are necessary for efficient VLP formation.

64 as sufficient for generating VLPs, efficient VLP production from the C-prM-E construct could be achie

65 ning virus-like particle-specific MAC-ELISA (VLP-MAC-ELISA).

66 High-Env VLPs, or hVLPs, were shown to be monodisperse and to dis

67 IV Env or a virus-like particle form of Env (VLP) induces potent and durable Env-specific antibody re

68 did not ubiquitinate eVP40 or enhance eVP40 VLP egress.

69 of eVP40 and a subsequent increase in eVP40 VLP egress, and (iii) an enzymatically inactive mutant o

70 ogenous WWP1 resulted in inhibition of eVP40 VLP egress, (ii) coexpression of WWP1 and eVP40 resulted

71 te efficient production and release of eVP40 VLPs.

72 ed vaccines or help to re-formulate existing VLP vaccines not naturally carrying immunostimulatory se

73 unctional interaction with eVP40 facilitates VLP and virus budding.

74 st viral protein coalescence and filamentous VLP formation and suggest that M-F interaction drives vi

75 further dissected the process of filamentous VLP formation.

76 ein coalescence and formation of filamentous VLPs that resembled wild-type virions.

77 ) were required for formation of filamentous VLPs, which, similar to those of wild-type virus, were a

78 have benefits for ZIKV and other flaviviral VLP vaccines.

79 production is applicable to other flavivirus VLP vaccine development, due to the similarity in viral

80 ndocytic F trafficking that is important for VLP assembly, not proteolytic F cleavage.

81 nal viral protein interactions important for VLP formation, we improve our understanding of the viral

82 g led to failure of F to function with M for VLP assembly.

83 Wild-type F functioned normally for VLP assembly even when its cleavage was prevented with a

84 on was found to be biologically relevant for VLP budding since (i) small interfering RNA (siRNA) knoc

85 antigens are often incorporated into foreign VLP systems to generate anti-RSV vaccine candidates.

86 igos do not interact with preformed RNA-free VLPs, so their effects must occur during particle assemb

87 parable to the curvature values derived from VLP size distributions.

88 onstruct alone was sufficient for generating VLPs, efficient VLP production from the C-prM-E construc

89 accinated with a single dose of the COBRA HA VLP vaccines elicited antibodies with HAI activity again

90 HAI activity after vaccination with COBRA HA VLP vaccines than COBRA preimmune ferrets vaccinated wit

91 a pigs were immunized with the resulting HIV VLPs through an intramuscular priming-intranasal boostin

92 In this study, HMPV VLPs containing viral fusion and matrix proteins elicite

93 r period against MD145, Grimsby, and Houston VLPs.

94 able efficient production, of authentic hRSV VLPs, we examined the associated requirements and mechan

95 at will facilitate future production of hRSV VLPs with defined shapes and compositions and may transl

96 or human respiratory syncytial virus (hRSV), VLP assembly is poorly understood and appears inefficien

97 Hybrid VLP binding with surface loop swapping between types ind

98 Avidities to heterotypic genogroup I VLPs were not sustained at day 35 after vaccination or G

99 Ligand binding of GII.17 cluster IIIb VLP was blocked only by antisera from mice immunized wit

100 tisera from mice immunized with cluster IIIb VLPs.

101 ages to elucidate a role for HA acylation in VLP assembly.

102 A related bottleneck in VLP-based products is the presence of cellular vesicles

103 onsensus in packaging and delivering CpGs in VLP-based vaccines is that both adjuvants and antigens s

104 While HA acylation did not influence VLP shape, lipid composition, or HA lateral spacing, acy

105 the immune responses to that from influenza VLPs without CCL28, or physically mixed with soluble CCL

106 Thus, GPI-anchored CCL28 in influenza VLPs act as a strong immunostimulator at both systemic a

107 to influenza VLPs without CCL28 or influenza VLPs physically mixed with sCCL28 (soluble) in mice.

108 month post-vaccination compared to influenza VLPs without CCL28 or influenza VLPs physically mixed wi

109 formation enhanced the recruitment of G into VLPs.

110 equences to Fstem allowed incorporation into VLPs.

111 e in the low-pH-dependent fusion of isolated VLPs to liposomes: fusion pores formed and expanded, as

112 cted subcutaneously with a dose of 10(9) KUN VLPs per animal twice with an interval of 4 weeks, and a

113 or in combination with HPV-16 and HPV-18 L1 VLPs) formulated with AS04 has the potential to provide

114 Rather than increasing the diversity of L1 VLPs, this vaccine contains VLPs based on a recombinant

115 himeric L1/L2 VLP was formulated with the L1 VLPs from the HPV-16/18 L1 vaccine.

116 r study demonstrated that the chimeric L1/L2 VLP is an effective vehicle for displaying two different

117 Hence, using the chimeric L1/L2 VLP may be a more cost-effective approach for vaccine fo

118 This chimeric L1/L2 VLP vaccine induced persistent immune responses and prot

119 ere further enhanced when the chimeric L1/L2 VLP was formulated with the L1 VLPs from the HPV-16/18 L

120 way to monitor disassembly of (19)F-labeled VLPs derived from bacteriophage Qbeta by (19)F NMR.

121 These novel proteins distinguish Lh from Lb VLPs; notably, some proteins specific to Lh VLPs possess

122 tructure-informed analyses of an abundant Lh VLP surface and spike-tip protein, p40, reveal similarit

123 Our studies suggest that Lh VLPs represent a new class of extracellular organelles a

124 VLPs; notably, some proteins specific to Lh VLPs possess sequence similarities with bacterial secret

125 mphatic system and show that also non-linked VLPs are efficiently co-delivered to the same APCs in ly

126 at had been vaccinated with HA, NA, NA + M2e-VLP and HA + NA + M2e-VLP were protected against homolog

127 Challenged NA and NA + M2e-VLP vaccinated mice mounted CD8+ T cell responses that c

128 with HA, NA, NA + M2e-VLP and HA + NA + M2e-VLP were protected against homologous H1N1 virus challen

129 Uniquely, immunization with M8-VLP stimulated a TH1-biased CD4 T cell response, as dete

130 beneficial when designing precision medicine VLP-based vaccines or help to re-formulate existing VLP

131 ellular distribution by confocal microscopy, VLP budding by thin-section transmission electron micros

132 ignificant potential of genetically modified VLPs as selective nanostructured probes for autonomous s

133 Our data show that MrNV VLPs package nucleic acids in a manner reminiscent of ot

134 algorithm combining the use of multiantigen VLP- and NS1-MAC-ELISAs was developed and can be practic

135 ns and allowed efficient production of mumps VLPs.

136 The use of mutant VLPs confirmed that the interaction nfGNPs-VLPs is not m

137 t VLPs confirmed that the interaction nfGNPs-VLPs is not mediated by the opposing superficial electro

138 eriments suggested that the nature of nfGNPs-VLPs interaction is non-covalent.

139 increasing ethanol concentrations on nfGNPs-VLPs complexes suggested hydrophobic interactions as the

140 Therefore, the nfGNPs-VLPs interaction described here should facilitate the de

141 ng IgA antibodies is sufficient to block NoV VLP binding to HBGAs.

142 Emerging CSF biomarkers NSE, VLP-1, HFABP, and YKL-40 were moderately associated with

143 zheimer's disease, whereas those of CSF NSE, VLP-1, HFABP, and YKL-40 were moderate (average ratios 1

144 flecting neurodegeneration (T-tau, NFL, NSE, VLP-1, and HFABP), APP metabolism (Abeta42, Abeta40, Abe

145 NoV strain) efficiently prevented binding of VLP strains MD145 (1987), Grimsby (1995), and Houston (2

146 cles were stained to confirm the presence of VLP in the urine samples.

147 s assembled from shotgun sequencing reads of VLP DNAs, we identified viruses that distinguish differe

148 ng ZIKV prM-E that produces large amounts of VLPs in the supernatant and a ZIKV C-prM-E cell line tha

149 r the study of the biophysical attributes of VLPs.

150 sm of Drosophila [6], but the composition of VLPs and their biotic nature have remained mysterious.

151 gy for the monitoring and quality control of VLPs.

152 ques allowing for specific discrimination of VLPs from host vesicular bodies.

153 tination of eVP40 by WWP1 enhances egress of VLPs and concomitantly decreases cellular levels of high

154 ut not c13C6, competitively inhibit entry of VLPs bearing EBOV GP into the host cell cytoplasm, witho

155 Moreover, if the F-driven formation of VLPs occurs through interactions with host cell machiner

156 e mainly through the effective inhibition of VLPs' binding to HBGA receptors and moderate inhibition

157 to HBGA receptors and moderate inhibition of VLPs' binding to their antibodies, without affecting the

158 structure of E to increase the production of VLPs in mammalian cells.

159 envelope protein enhances the production of VLPs.

160 highly effective to inhibit both strains of VLPs' bindings to histo-blood group antigens (HBGA) rece

161 l cytoplasm, without blocking trafficking of VLPs to NPC1(+) endolysosomes, where EBOV fuses.

162 tion using AS04-adjuvanted vaccines based on VLP chimeras of L1 with one or two L2 epitopes.

163 Furthermore, our data on VLP and, by hypothesis, virus suggests that HA acylation

164 of CDots also exhibited inhibitory effect on VLP's binding to their respective antibodies, but much l

165 Specifically, Fel d 1 on VLPs induced strongly increased protective IgG responses

166 Firstly, Fel d 1 on VLPs showed a strongly impaired ability to bind to surfa

167 binding, repetitively displayed allergen on VLPs failed to cause mast cell activation.

168 te that repetitively displaying allergens on VLPs increases their immunogenicity while reducing their

169 ivation in its free form versus displayed on VLPs and we performed allergen binding studies by surfac

170 ized mast cells whereas Fel d 1 displayed on VLPs fails to induce mast cell activation.

171 d intact, and no degradation was observed on VLPs' capsid proteins.

172 have shown that CpGs can be packaged in one VLP and mixed with another VLP displaying the antigen pr

173 nd physically distinct from M-only or F-only VLPs.

174 exposed to live RESTV, inactivated RESTV, or VLPs containing RESTV GP, indicating that RESTV GP does

175 while strongly discriminating against other VLP types.

176 Our VLP-based platform provides a source for a ZIKV vaccine

177 We have devised a virus like particle (VLP) carrier based on the hepatitis B core antigen (HBcA

178 this study, we report a virus-like particle (VLP) for building a 3D plasmonic nanostructure in soluti

179 tested in mice using a virus-like particle (VLP) format for the elicitation of broadly reactive, fun

180 ffinity ligands using a virus-like particle (VLP) from the 2006 GII.4 Minerva strain of norovirus.

181 sed P. vivax vaccine, a virus-like particle (VLP) known as Rv21, able to provide 100% sterile protect

182 ted a bivalent chimeric virus-like particle (VLP) presenting the VP1 (aa208-222) and VP2 (aa141-155)

183 in the development of a virus-like particle (VLP) vaccine as well as small-molecule drugs targeting a

184 .1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophos

185 ed 2 bivalent norovirus virus-like particle (VLP) vaccine candidate formulations in healthy adults ag

186 vercome this, we used a virus-like particle (VLP) vaccine platform (PP7) for conformationally-restric

187 Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being eval

188 accinating ferrets with virus-like particle (VLP) vaccines expressing COBRA HA proteins elicited anti

189 n and use of virus-free virus-like particle (VLP) vaccines that mimic the "empty" capsids (ECs) norma

190 nti-hRSV approaches are virus-like particle (VLP) vaccines, which, based on resemblance to virus or v

191 RSV F virus-like particle (VLP) would be an efficient vaccine platform conferring p

192 We used a virus-like particle (VLP)-based approach to develop a vaccine and a microneut

193 tein 2 (M2e) fused to a virus-like particle (VLP).

194 ted to bind the Type 16 virus-like-particle (VLP) formed by the self-assembling capsid protein L1.

195 or capsid protein (L1) virus-like particles (VLP) and are highly efficacious against the development

196 We used virus-like particles (VLP) to study the effect of acylation on morphology, pro

197 titer (BT50) values of virus-like particles (VLPs) against pig gastric mucin (PGM) using 4 VLPs that

198 release of VP40-driven virus-like particles (VLPs) and infectious virus.

199 ction between HPV16 L1 virus-like particles (VLPs) and non-functionalized GNPs (nfGNPs) resulting in

200 n standards were used: Virus-Like Particles (VLPs) and synthetic beads with a mean diameter of 53nm a

201 Virus-like particles (VLPs) are attractive as a vaccine concept.

202 Virus-like particles (VLPs) are non-infectious self-assembling nanoparticles,

203 Virus-like particles (VLPs) are stable protein cages derived from virus coats.

204 e-specific assembly of virus-like particles (VLPs) at much higher fidelity and yield than in the abse

205 Selected huNoV-like particles (VLPs) bound the glycocalyx of HIOs with matched HBGA phe

206 p55 (protein) or with virus-like particles (VLPs) containing SIVmac239 Env and Gag.

207 ecombinantly expressed virus-like particles (VLPs) could address these inherent problems.

208 crystalline, spherical virus-like particles (VLPs) derived from Gag.

209 nogens, all expressing virus-like particles (VLPs) displaying membrane-anchored trimeric Env.

210 Virus-like particles (VLPs) have become a promising platform for vaccine produ

211 Virus-like particles (VLPs) have been extensively explored as nanoparticle veh

212 fficient production of virus-like particles (VLPs) in transfected cells.

213 Spiked virus-like particles (VLPs) in wasp venom have clearly been linked to wasps' s

214 tivated EBOV and Ebola virus-like particles (VLPs) induced NF-kappaB activation mediated by Toll-like

215 apillomavirus (HPV) L1 virus-like particles (VLPs) is the structural basis of prophylactic vaccines.

216 repetitive fashion on virus-like particles (VLPs) may fulfill these criteria.

217 Virus like particles (VLPs) of P22 containing ziconotide were successfully tra

218 HPV vaccines based on virus-like particles (VLPs) of the L1 major capsid protein from HPV-2, -4, or

219 ensed vaccines contain virus-like particles (VLPs) of the L1 major capsid protein from two, four, or

220 the structure of MrNV virus-like particles (VLPs) produced by recombinant expression of the capsid p

221 Antigenicity of virus-like particles (VLPs) representative of clusters I, II, and IIIb GII.17

222 oduction and egress of virus-like particles (VLPs) that accurately mimic the budding of infectious vi

223 oordinated assembly of virus-like particles (VLPs) that were morphologically and physically distinct

224 rmation and budding of virus-like particles (VLPs) which mimic the budding process and morphology of

225 Virus-like particles (VLPs) with increased density of Env are being pursued fo

226 Virus-like particles (VLPs), comprised of viral structural proteins devoid of

227 es, in particular into virus-like particles (VLPs), improves the pharmacological characteristics of C

228 rom the disassembly of virus-like particles (VLPs), were incubated with nuclear extracts to provide a

229 engue vaccine by using virus-like particles (VLPs), which are noninfectious because they lack the vir

230 e vaccine by utilizing virus-like particles (VLPs).

231 ys 20 spikes mimicking virus-like particles (VLPs).

232 V vaccines composed of virus-like particles (VLPs).

233 ization with influenza virus-like particles (VLPs).

234 ient for production of virus-like particles (VLPs).

235 erisation scaffolds or virus like particles (VLPs).

236 packaged within Qbeta virus-like particles (VLPs).

237 nduce the formation of virus-like particles (VLPs).

238 ity to human norovirus virus-like-particles (VLPs), GI.1 and GII.4 VLPs.

239 ake of filamentous EBOV viruslike particles (VLPs) expressing the EBOV glycoprotein (GP) occurs relat

240 embedded in filamentous viruslike particles (VLPs).

241 V prM-E proteins that constitutively produce VLPs as well as a cell line expressing ZIKV C-prM-E prot

242 ag proteins, the other Gag proteins produced VLPs as confirmed by TEM, and morphological differences

243 otein (AP; 18% protein) or very low protein (VLP; 2% protein) in an established murine model of influ

244 ggregation and the stabilization of purified VLPs.

245 he production of synthetically stabilized PV VLPs in plants.

246 mbination of RNAi scaffold design with Qbeta VLP packaging is demonstrated to be target-specific and

247 demonstrate that chemically-conjugated Qbeta VLPs elicited the highest quantity of antibodies, while

248 glycoprotein (GP) occurs relatively quickly, VLPs only begin to enter the cytoplasm after a 30-min la

249 ligase that ubiquitinates VP40 and regulates VLP egress.

250 tegy extracellular vesicle (MSEV) to replace VLP.

251 for formation of wild-type-virus-resembling VLPs, the contributions of these proteins to morphology,

252 Electrical impedance spectroscopy revealed VLP saturation on impedance sensor surface with the cove

253 We generated sets of chimeric RHDV VLPs by insertion of the foreign B-cell epitopes at thre

254 presented here indicated that chimeric RHDV VLPs elicit potent protective humoral responses against

255 To evaluate the ability of chimeric RHDV VLPs to elicit protective humoral responses against fore

256 nd that M could no longer induce significant VLP release but retained the ability to be incorporated

257 A single VLP protein boost displaying trimeric gp160 adjuvanted w

258 to incorporate an M1 layer within spheroidal VLP, and filamentous particles incorporated increased nu

259 Injecting SpyCatcher-VLPs decorated with a malarial antigen efficiently induc

260 quantitative covalent coupling to SpyCatcher-VLPs after mixing with SpyTag-linked to malaria antigens

261 stability and postulate that such stabilized VLPs could be used as novel vaccines.

262 e applied as candidates to synthesize stable VLPs as future genome-free poliovirus vaccines.

263 ity to an immunologically novel GII.4 strain VLP correlated with preexisting Ab titer to an ancestral

264 ategy for the creation of putative, targeted-VLP delivery systems.

265 against more H1N1 viruses in the panel than VLP vaccines expressing wild-type HA proteins.

266 Our proteomics studies reveal that VLPs lack viral coat proteins but possess a pharmacopoei

267 Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no

268 Immunization studies in mice showed that VLPs generated higher neutralizing antibody titers than

269 The VLP self-assembly dynamics were studied by the continuou

270 The VLP-functionalized impedance sensors responded to 12ng/m

271 The VLP-RNAi assembles upon co-expression of CP and the RNAi

272 To facilitate the VLP platform, we generated a stable cell line expressing

273 Importantly, the VLP protein boost increased binding antibody against sca

274 was used to confirm positive results in the VLP-MAC-ELISA, the specificity of serodiagnosis, especia

275 ces in the overall assay performances of the VLP- and NS1-MAC-ELISAs.

276 anoparticles are precisely positioned on the VLP by directed self-assembly techniques.

277 the research and development that led to the VLP vaccines; discusses their safety, efficacy, and shor

278 of the target antibody is 9.1ng/ml using the VLP-based impedimetric microsensor.

279 ralization antibody responses induced by the VLPs were significantly higher than those with DNA or re

280 r this critical alpha-helical segment in the VLPs.

281 ), and general morphological features of the VLPs by cryogenic transmission electron microscopy (cryo

282 ticipate in the arrangement of nfGNPs on the VLPs surface.

283 In addition, we showed coupling to the VLPs for peptides relevant to cancer from epidermal grow

284 Thus, VLPs containing a stabilized prefusion form of the RSV F

285 y of Tobacco mosaic virus-like particle (TMV VLP) sensing probes using an impedimetric microsensor pl

286 TMV VLPs are high surface area macromolecules with nanorod s

287 Genetically modified TMV VLPs express both surface attachment-promoting cysteine

288 The pre-binding of heparan sulfate to VLPs inhibited the binding of both N-mAbs to the antigen

289 After CDots treatments, VLPs remained intact, and no degradation was observed on

290 Two VLP doses conferred sterilizing immunity in C57BL/6 mice

291 rget cells in vivo at levels seen when using VLPs containing both CpGs and chemically conjugated anti

292 We present evidence that Ebola virus VLPs stimulate induction of SOCS3 as well as proinflamma

293 While VLPs were not produced by the representative Beta- and E

294 bition of GFP expression in human cells with VLP-RNAi.

295 correlate was apparent for immunization with VLP-NP or alum as the adjuvant.

296 than COBRA preimmune ferrets vaccinated with VLP vaccines expressing wild-type HA proteins.

297 Our findings support immunization with VLPs containing trimeric Env as a strategy to augment pr

298 Virus infection or vaccination with VLPs containing hemagglutinin from A/PR8/34 influenza vi

299 HBcAg-zDIII VLPs are shown to be highly immunogenic, as two doses el

300 Notably, HBcAg-zDIII VLPs-elicited antibodies did not enhance the infection o

301 also demonstrated that the Zika virus (ZIKV) VLP production level was enhanced by introducing the sam